Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AXL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AXL ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View AXL Products |
| Gene Delivery | AXL Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. |
View AXL Products |
| Benchmark Ab | Anti-AXL (Sequence of Enapotamab) Recombinant positive control for assay benchmarking. |
View AXL Products |
| Validator | AXL siRNA Set For knockdown verification and specificity checks. |
View AXL Products |
| Related Target A | GAS6 Primary endogenous ligand of AXL for receptor activation assays. |
View GAS6 Products |
| Related Target B | EGFR Resistance bypass pathway commonly co-targeted in NSCLC. |
View EGFR Products |
| Related Target C | MER TAM family counter-target for selectivity profiling. |
View MER Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization Optimization | High-purity ECD-Fc fusion proteins (HEK293 expressed) ensuring native conformation for accurate binding kinetics and internalization assays. |
| TAM Subfamily Counter Screening | Strictly sequence-verified homolog panel proteins (AXL, TYRO3, MER) available for rigorous off-target evaluation. |
| Lack of Positive Controls | Sequence-verified clinical benchmark antibodies available to establish reliable assay baselines. |
| False Positives in Cell Assays | Validated siRNA sets included for robust genetic knockdown specificity checks. |
Live AXL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AXL therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and highly selective Small Molecule Tyrosine Kinase Inhibitors (TKIs). Because AXL overexpression is a major driver of epithelial-mesenchymal transition (EMT) and resistance to targeted therapies (such as EGFR inhibitors), combination strategies are dominating the clinical pipeline. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal payload delivery mechanisms and overcoming tumor microenvironment immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (TKI) | BerGenBio, Astellas, Exelixis | NSCLC, AML, Melanoma | Selectivity Assay (Need High-Purity TAM family Kinase Domains) |
| ADC | Genmab, BioAtla | Solid Tumors (Ovarian, NSCLC) | Internalization Assay (Need HEK293-expressed ECD-Fc) |
| Bispecific / mAb | Zymeworks, MabDiscovery | Refractory Cancers | Epitope Mapping (Need Cross-reactive Cyno/Mouse Orthologs) |